The bicyclic nucleoside analogue (BCNA) Cf1743 and its orally bioavailable prodrug FV-100 have unique potential as varicella-zoster virus (VZV) inhibitors to treat herpes zoster (shingles) and the therewith associated pain, including post-herpetic neuralgia (PHN). The anti-VZV activity of Cf1743 depends on a specific phosphorylation by the VZV-encoded thymidine kinase (TK). The target of antiviral action is assumed to be the viral DNA polymerase (or DNA synthesis in the virus-infected cells).
Rebecca Sienaert, Lieve Naesens, Andrea Brancale, Antonella Carangio, Graciela Andreï, Robert Snoeck, André B. P. Kuilenburg, De Clercq Erik, Christopher McGuigan, Jan Balzarini
Discussion(0)
No comments yet. Be the first to comment.